Related Experiment Video
Updated: May 21, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
X-inactivation in Fabry disease
Deborah Elstein1, Ella Schachamorov, Rachel Beeri
1Gaucher Clinic, Shaare Zedek Medical Center, Hebrew University, Hadassah Medical School, Ein Karem, Jerusalem, Israel. elstein@szmc.org.il
Background:
Fabry disease is one of three X-linked lysosomal disorders. Because of X-chromosome inactivation (XCI), wherein there is (random) transcriptional silencing of one of the X-chromosomes in each female cell, females are mosaic for the expression of (some) X-linked genes. Thus, based on penetrance and expression, some females heterozygous for Fabry disease are symptomatic but not to the same degree as hemizygous males. The purpose of this study was to ascertain whether skewed X-inactivation favoring the mutant α-galactosidase A allele exists in our cohort of female heterozygotes of Fabry disease.
Method:
All patients were evaluated by physical examination and ascribed disease-specific severity sub-scores for each of the four categories (cardiac, renal, neurological, general) and a total score using the Mainz Severity Score Index (MSSI). Blood samples were drawn for enzymatic activity of α-galactosidase A and for DNA extraction for analysis for α-galactosidase A mutations. XCI ratios were determined from peripheral blood leukocyte samples. The X-chromosome inactivation ratio was determined in each heterozygote.
Results:
Of 77 samples, only 18.2% were highly skewed (80/20). Only 14.3% of samples with nonsense mutations were highly skewed. There were no correlations between the XCI ratios and age, enzymatic activity of α-galactosidase A, MSSI sub-scores or total score, or with the clinical signs of cardiac involvement, neuropathic pain, or proteinuria.
Conclusion:
These findings are comparable with others in Fabry disease, i.e., essentially the same as seen in normal non-elderly female population, raising the question of the mechanism underlying symptomatic phenotypic expression in heterozygous females with Fabry disease.
Insights
In Fabry disease, X-chromosome inactivation (XCI) patterns in heterozygous females do not correlate with disease severity. This suggests other mechanisms cause symptoms in these women.
Area of Science:
- Genetics
- Biochemistry
- Medical Genetics
Background:
- Fabry disease is an X-linked lysosomal disorder.
- X-chromosome inactivation (XCI) creates mosaicism in females, leading to variable disease expression.
- Heterozygous females can be symptomatic, but often less severely than males.
Purpose of the Study:
- To investigate if skewed X-chromosome inactivation (XCI) favoring the mutant allele occurs in female Fabry disease heterozygotes.
- To explore the relationship between XCI patterns and clinical manifestations in these patients.
Main Methods:
- Physical examinations and severity scoring using the Mainz Severity Score Index (MSSI).
- Assays for α-galactosidase A enzymatic activity and mutation analysis.
- Determination of XCI ratios from peripheral blood leukocyte samples.
Main Results:
- Only 18.2% of samples showed highly skewed XCI (80/20 ratio).
- No significant correlations were found between XCI ratios and age, enzyme activity, MSSI scores, or specific clinical signs (cardiac, pain, proteinuria).
- Highly skewed XCI was less frequent in samples with nonsense mutations (14.3%).
Conclusions:
- The observed XCI patterns in female Fabry heterozygotes are similar to the general female population.
- The findings raise questions about the underlying mechanisms driving symptomatic disease expression in heterozygous females.
- Further research is needed to understand the factors contributing to phenotypic variability in female Fabry disease patients.
Related Concept Videos
X-inactivation
X-Inactivation
Inheritance of Chromatin Structures
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Incomplete Dominance
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...

